In its slimmed-down version, the legislation would likely cover fewer than half of the estimated 30 to 40 million uninsured individuals in the United States. Nevertheless, the bill may face funding hurdles—especially in this economic climate. "While both parties might agree on what should be in the bill," said Steven Usdin, senior editor at BioCentury Publications during a roundtable on the subject at the Biotechnology Industry Organizations' annual CEO and Investor Conference in early February, "they disagree on how to fund it." In other words, the reform measures may still be too rich for lawmakers' blood.
Ironically, healthy people continue to opt out of insurance plans, causing insurers to raise their rates even more. If this continues, health insurance will cover only the sickest, wealthiest Americans—a scenario that can't be good for anyone, including the pharmaceutical industry.Not to be deterred, the White House made one more push in early February to bring all the parties back to the table. The president issued an invitation to Democrats and Republicans to participate in a televised summit in which representatives will attempt to reach a consensus about the contents—and maybe the financial support—of a healthcare bill. Fortunately, representatives from both parties have accepted the invitation.
The meeting may well represent the last chance for lawmakers to craft a plan with some meat on its bones at a price that does not require a king's ransom.
Michelle Hoffman is editor-in-chief of Pharmaceutical Technology. Send your thoughts and story ideas to firstname.lastname@example.org
1. New York Times, Jan. 21, 2010, http://www.nytimes.com/2010/01/22/health/policy/22health.html?scp=1&sq=A%20New%20Search%20for%20Consensus%20on%20Health%20Care%20Bill&st=cse/, accessed Feb. 22, 2010.